New drug cocktail may show promise in NSCLC patients
A drug approved by the Food and Drug Administration for melanoma in combination with a common cholesterol-lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.